ELOX
Eloxx Pharmaceuticals, Inc. [ELOX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ELOX Stock Summary
Top 10 Correlated Stocks
ELOX
In the News
ELOX Financial details
Company Rating
Neutral
Market Cap
3.21M
Income
-20.48M
Revenue
0
Book val./share
-7.3
Cash/share
1.74
Dividend
-
Dividend %
-
Employees
18
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-0.15
Forward P/E
-
PEG
0.02
P/S
-
P/B
-0.16
P/C
0.56
P/FCF
-0.2
Quick Ratio
0.2
Current Ratio
0.24
Debt / Equity
-0.29
LT Debt / Equity
-0.13
-
-
EPS (TTM)
-9.07
EPS next Y
-
EPS next Q
-
EPS this Y
-56.36%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-33.16%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0.68%
Inst Trans
0%
ROA
-350%
ROE
129%
ROC
1.11%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.4-10.9
52W High
-
52W Low
-
RSI
50
Rel Volume
0.07
Avg Volume
9.09K
Volume
641
Perf Week
-3.47%
Perf Month
13.35%
Perf Quarter
-41.96%
Perf Half Y
-59.54%
-
-
-
-
Beta
2.758
-
-
Volatility
0.02%, 0.06%
Prev Close
1.3%
Price
0.975
Change
-0.76%
ELOX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -58.19 | -53.46 | -34.47 | -38.15 | -16.65 | |
| Operating cash flow per share | -38.68 | -41.4 | -28.08 | -20.01 | -14.7 | |
| Free cash flow per share | -38.97 | -41.44 | -28.08 | -20.06 | -14.73 | |
| Cash per share | 59.94 | 59.14 | 24.59 | 24.17 | 8.87 | |
| Book value per share | 52.92 | 38.06 | 10.2 | 12.8 | -4.92 | |
| Tangible book value per share | 52.92 | 38.06 | 10.2 | 12.8 | -4.92 | |
| Share holders equity per share | 52.92 | 38.06 | 10.2 | 12.8 | -4.92 | |
| Interest debt per share | 0.01 | 18.26 | 13.4 | 8.41 | 7.08 | |
| Market cap | 389.56M | 280.14M | 159.7M | 49.67M | 3.94M | |
| Enterprise value | 340.96M | 273.41M | 147.07M | 20.86M | -1.88M | |
| P/E ratio | -8.26 | -5.51 | -4.62 | -0.74 | -0.11 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -12.42 | -7.11 | -5.67 | -1.42 | -0.12 | |
| PFCF ratio | -12.33 | -7.1 | -5.67 | -1.42 | -0.12 | |
| P/B Ratio | 9.08 | 7.74 | 15.61 | 2.22 | -0.37 | |
| PTB ratio | 9.08 | 7.74 | 15.61 | 2.22 | -0.37 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -7.39 | -5.59 | -5.15 | -0.32 | 0.06 | |
| EV to operating cash flow | -10.87 | -6.94 | -5.22 | -0.6 | 0.06 | |
| EV to free cash flow | -10.79 | -6.93 | -5.22 | -0.59 | 0.06 | |
| Earnings yield | -0.12 | -0.18 | -0.22 | -1.34 | -9.15 | |
| Free cash flow yield | -0.08 | -0.14 | -0.18 | -0.71 | -8.09 | |
| Debt to equity | 0 | 0.44 | 1.18 | 0.6 | -1.26 | |
| Debt to assets | 0 | 0.27 | 0.45 | 0.3 | 0.63 | |
| Net debt to EBITDA | 1.05 | 0.14 | 0.44 | 0.44 | 0.17 | |
| Current ratio | 6.45 | 4.89 | 2.63 | 4.37 | 0.87 | |
| Interest coverage | -6.8K | -31.28 | -23.74 | -52.44 | -17.66 | |
| Income quality | 0.66 | 0.77 | 0.81 | 0.52 | 0.88 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -1.09 | -0.07 | 0 | -0.09 | -0.09 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 263.21 | 213.96 | 88.93 | 104.81 | 42.93 | |
| ROIC | -1.11 | -0.99 | -1.53 | -1.8 | -10.18 | |
| Return on tangible assets | -0.93 | -0.86 | -1.31 | -1.48 | -1.71 | |
| Graham Net | 50.31 | 35.64 | 8.39 | 11.16 | -5.81 | |
| Working capital | 42.53M | 45.9M | 16.06M | 33.53M | -2.96M | |
| Tangible asset value | 42.91M | 36.21M | 10.23M | 22.38M | -10.66M | |
| Net current asset value | 42.53M | 34.98M | 9.65M | 20.73M | -11.65M | |
| Invested capital | 0 | 0.44 | 1.18 | 0.6 | -1.26 | |
| Average receivables | 0 | 13K | 13K | 0 | 0 | |
| Average payables | 1.14M | 1.31M | 1.18M | 930K | 2.2M | |
| Average inventory | 0 | 354K | 354K | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -1.1 | -1.4 | -3.38 | -2.98 | 3.38 | |
| Capex per share | -0.29 | -0.04 | 0 | -0.05 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -3.47 | -2.92 | -2.88 | -1.96 | -1.31 | |
| Operating cash flow per share | -3.21 | -2.61 | -3.15 | -0.93 | -1.26 | |
| Free cash flow per share | -3.23 | -2.61 | -3.15 | -0.93 | -1.26 | |
| Cash per share | 11.33 | 8.87 | 2.26 | 1.96 | 1.74 | |
| Book value per share | -2.3 | -4.92 | -7.52 | -8.41 | -7.3 | |
| Tangible book value per share | -2.3 | -4.92 | -7.52 | -8.41 | -7.3 | |
| Share holders equity per share | -2.3 | -4.92 | -7.52 | -8.41 | -7.3 | |
| Interest debt per share | 6.42 | 6.45 | 3.1 | 2.86 | 2.18 | |
| Market cap | 14.73M | 3.94M | 5.44M | 8.61M | 13.22M | |
| Enterprise value | 3.59M | -1.88M | 6.77M | 10.38M | 14.2M | |
| P/E ratio | -0.49 | -0.16 | -0.22 | -0.5 | -0.92 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -2.12 | -0.7 | -0.8 | -4.17 | -3.83 | |
| PFCF ratio | -2.11 | -0.7 | -0.8 | -4.17 | -3.83 | |
| P/B Ratio | -2.96 | -0.37 | -0.33 | -0.46 | -0.66 | |
| PTB ratio | -2.96 | -0.37 | -0.33 | -0.46 | -0.66 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -0.52 | 0.33 | -1.32 | -2.67 | -3.86 | |
| EV to operating cash flow | -0.52 | 0.33 | -0.99 | -5.02 | -4.12 | |
| EV to free cash flow | -0.51 | 0.33 | -0.99 | -5.02 | -4.12 | |
| Earnings yield | -0.51 | -1.6 | -1.15 | -0.5 | -0.27 | |
| Free cash flow yield | -0.47 | -1.44 | -1.25 | -0.24 | -0.26 | |
| Debt to equity | -2.69 | -1.26 | -0.38 | -0.33 | -0.29 | |
| Debt to assets | 0.5 | 0.63 | 0.87 | 1.02 | 0.95 | |
| Net debt to EBITDA | 1.63 | 1.03 | -0.26 | -0.46 | -0.27 | |
| Current ratio | 1.18 | 0.87 | 0.33 | 0.25 | 0.24 | |
| Interest coverage | -14.61 | -10.38 | -11.31 | -18 | -15.48 | |
| Income quality | 0.93 | 0.9 | 1.09 | 0.48 | 0.96 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.25 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 13.39 | 17.97 | 22.06 | 19.26 | 14.65 | |
| ROIC | -0.81 | -1.86 | 0.63 | 0.36 | 0.26 | |
| Return on tangible assets | -0.28 | -0.3 | -0.87 | -0.72 | -0.59 | |
| Graham Net | -3.37 | -5.81 | -8.58 | -9.16 | -7.76 | |
| Working capital | 3.99M | -2.96M | -13.06M | -15.87M | -17.84M | |
| Tangible asset value | -4.98M | -10.66M | -16.29M | -18.6M | -20.05M | |
| Net current asset value | -6.19M | -11.65M | -17.09M | -19.21M | -20.46M | |
| Invested capital | -2.69 | -1.26 | -0.38 | -0.33 | -0.29 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 1.76M | 2.31M | 2.73M | 2.78M | 3.13M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 1.51 | 0.59 | 0.38 | 0.23 | 0.18 | |
| Capex per share | -0.02 | 0 | 0 | 0 | 0 |
ELOX Frequently Asked Questions
What is Eloxx Pharmaceuticals, Inc. stock symbol ?
Eloxx Pharmaceuticals, Inc. is a US stock , located in Watertown of Ma and trading under the symbol ELOX
What is Eloxx Pharmaceuticals, Inc. stock quote today ?
Eloxx Pharmaceuticals, Inc. stock price is $0.975 today.
Is Eloxx Pharmaceuticals, Inc. stock public?
Yes, Eloxx Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 9.09K
- Market Capitalization 3.21M
- Employee 18
- CEO Mr. Sumit Aggarwal M.B.A.
- Headquarters Watertown,MA,US
- IPO Date 1999-04-26
-
Website
https://www.eloxxpharma.com 
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
